Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tolododekin alfa + cetrelimab (Ankyra Therapeutics)
- Development stage
- Phase 1
- Lead developer
- Ankyra Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Tolododekin alfa (ANK-101) is an anchored interleukin-12 (IL-12) immunotherapy designed for intratumoral administration. It consists of a recombinant human IL-12 (tolododekin alfa) conjugated to an anchoring moiety that binds to the extracellular matrix (ECM) within the tumor microenvironment. This anchoring mechanism is intended to prevent systemic leakage of IL-12, thereby reducing systemic toxicity while maintaining high local concentrations to stimulate an anti-tumor immune response. In combination with anti-PD-1/PD-L1 antibodies, such as the PD-1 inhibitor cetrelimab, the therapy aims to overcome the immunosuppressive tumor microenvironment and enhance T-cell mediated anti-tumor activity. The combination is currently being evaluated in Phase 1 clinical trials for patients with advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC) that has progressed after initial treatments.
- Other names
- tolododekin alfa + anti-PD-1/PD-L1 antibodyANK-101 + cetrelimab
02
Targets
IL-12R (Interleukin-12 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tolododekin alfa + cetrelimab (Ankyra Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tolododekin alfa + cetrelimab (Ankyra Therapeutics).